In this issue:
Management of BM in NSCLC varies widely in Europe
ALK variant matters for ALK TKI selection
Examining the impact of TMB on immunotherapy efficacy
Pazopanib maintenance in extensive-disease SCLC
Long-term safety with gefitinib in NSCLC
ALT-803 + nivolumab shows promise in pre-treated NSCLC
Durvalumab may have a role in EGFR+/ALK+ NSCLC
Alectinib for crizotinib-pre-treated ALK+ NSCLC
Consider cell blocks for PD-L1 testing in advanced NSCLC
Are antibiotics causatively linked to ICI resistance?
Please login below to download this issue (PDF)